Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma

Table 2 Prognostic factors for OS (N = 74)

Variables	Univariate analysis		Multivariate analysis
Variables	HR (95% CI)	P	HR (95% CI)	P
ECOG
0–1 versus > 1	0.33 (0.15, 0.71)	0.005	0.34 (0.15, 0.78)	0.011
Oligometastasis
Yes versus no	0.22 (0.07, 0.74)	0.015	0.28 (0.08, 0.97)	0.044
Treatment
anti-PD-1/TA + SBRT vs anti-PD-1/TA alone	0.42 (0.20, 0.90)	0.026	0.43 (0.19, 0.98)	0.044
Duration of first-line therapy
≥8.6 m versus 8.6 m	0.46 (0.22, 0.99)	0.046	0.42 (0.19, 0.91)	0.027

ISSN: 1748-717X